Does Bayer's Acquisition of Monsanto Make Sense?

December 27, 2016 | State of the Market Report

This year, the agricultural industry underwent a dramatic shake-up as a series of mega-mergers and acquisitions occurred; one of those was Bayer’s acquisition of Monsanto. We conducted an in-depth analysis of the future combined company’s strengths and weaknesses across four technology categories; crop and seed traits, Digital Ag, synthetic agrochemicals, and biologicals. We examined each individual company's external innovations in these technology families by examining recent licenses, partnerships, and acquisitions. We also examined each individual company's internal innovations in these technology families by examining recently granted intellectual property. The analysis reveals if Bayer's acquisition of Monsanto made sense, and if it was truly worth the $66 billion price tag.

Coverage Areas

  • Accelerating Materials Innovation
  • Agro Innovation
  • Consumer Choices in Food, Health, and Wellness
  • Corporate Strategic Intelligence: Chemicals and Materials

Table of Contents

  • Title page
  • Introduction
  • Methodology
  • Crop and seed traits
  • Digital Ag
  • Synthetic agrochemicals
  • Biologicals
  • What to expect from the future combined company
  • Outlook

Lead Analyst

Laura Lee
Research Associate
+1 (857) 702-3923

Login to View This Research

Already a Lux Client?

Sign In

Not a Lux Client?

Talk to Lux Research now and learn the benefits of becoming a member.

Lux Research

  • Helps clients find new business opportunities from emerging technologies in the physical and life sciences
  • Offers ongoing technology and market intelligence, as well as market data and consulting services
  • Now serves over 250 clients on six continents – multinational corporations, investors, governments, and SMEs
  • Has a Global reach, with offices in Boston, New York, Amsterdam, Singapore, and Tokyo
  • Combines deep technical expertise with business analysis to support strategic decisions

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 (0) 20-3460840

For APAC (Singapore)
+65 6592-6978